Allogene Therapeutics Inc. has raised $744m to date, including its $324m initial public offering on Oct. 10, and with its coffers full of cash Chief Financial Officer Eric Schmidt tells Scrip that the allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developer is ready to "go full throttle."
Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.
